Keep tabs on your favorite ETFs with a personalized weekly tracker. Create a Watchlist now →
XBIvsLFSCETF Comparison
SPDR S&P Biotech ETF (XBI) belongs to the US Health Care segment. F/m Emerald Life Sciences Innovation ETF (LFSC) is part of the Life Sciences segment. Both ETFs have the same top 3 sector exposures: and Health Care. XBI is less expensive with a Total Expense Ratio (TER) of 0.35%, versus 0.79% for LFSC. XBI is up 3.65% year-to-date (YTD) with -$59M in YTD flows. LFSC performs worse with -4.3% YTD performance, and +$5M in YTD flows. Run a side-by-side ETF comparison of XBI and LFSC below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
XBI vs LFSC performance and flow charts
Performance
Cumulative Flows
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | XBI LFSC | +1.38%-2.61% | +3.11%-9.88% | +3.65%-4.30% | +47.21%+55.33% | +63.16%n/a | -13.71%n/a |
| Flows | XBI LFSC | -$4M+$6M | -$179M+$6M | -$59M+$5M | +$90M+$16M | -$1.64B- | +$1.20B- |
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | XBI LFSC | +25.68%+21.93% | +28.04%+28.55% | +27.26%n/a | +32.91%n/a |
| Max drawdown | XBI LFSC | -8.19%-12.82% | -21.44%-19.03% | -32.94%n/a | -57.63%n/a |
| Max drawdown duration | XBI LFSC | 48d76d | 141d70d | 331dn/a | 1822dn/a |
XBI | LFSC | |
Last sale 3/12/2026 at 1:30 PM | $122.64 | $33.97 |
| Previous close 03/11/2026 | $126.38 | $35.01 |
| Consolidated volume 03/11/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Create an account to view replication metrics
XBI | LFSC | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
XBI | LFSC | |
|---|---|---|
| Last price | $122.64 | $33.97 |
| 1D performance | -2.96% | -2.99% |
| AuM | $8.10 B | $93.79 M |
| E/R | 0.35% | 0.79% |
XBI | LFSC | |
|---|---|---|
| Management strategy | Passive | Active |
| Provider | SPDR | Emerald Group |
| Benchmark | S&P Biotechnology Select Industry Index | - |
| N° of holdings | 123 | 34 |
| Asset class | Equities | - |
| Trailing 12m distribution yield | Join | Join |
| Inception date | January 31, 2006 | October 31, 2024 |
| ESG | No | No |
Countries
Sectors
Diversification
Total weight of top 15 holdings out of 15
Total weight of top 15 holdings out of 15
Top 15 holdings
How have the XBI and LFSC ETFs performed in 2026?
As of March 11, 2026, XBI is up 3.65% year-to-date (YTD), while LFSC has lost -4.3%. That puts XBI better performer ahead so far this year.
Which ETF is attracting more investor money: XBI or LFSC?
Year-to-date, the XBI ETF saw -$59M in flows, compared to +$5M for LFSC.
Which ETF is more volatile: XBI or LFSC?
Over the past year, XBI had a volatility of 28.04%, while LFSC experienced 28.55%.
Which ETF is bigger: XBI or LFSC?
As of March 11, 2026, XBI holds $8.10 B in assets under management (AUM), while LFSC manages $93.79 M.
What sectors do the XBI and LFSC ETFs invest in?
XBI leans toward sectors like Health Care. Meanwhile, LFSC focuses on Health Care.
What are the top holdings of the XBI ETF and LFSC ETF?
XBI top holdings include MODERNA INC, MIRUM PHARMACEUTICALS INC and REVOLUTION MEDICINES INC. LFSC holds in its top three: COGENT BIOSCIENCES, LIVANOVA and GUARDANT HEALTH INC.
Which ETF is more diversified: XBI or LFSC?
XBI holds 149 securities with 21.6% of its assets in the top 15. LFSC has 42 securities and a top 15 weight of 68.94%.
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
Are Biotechnology ETFs In the Midst of a Comeback?
Two biotech ETFs to watch for the rest of 2022 and beyond
Biotech ETFs – Investing in Health Innovation
Active Trader Report: Use of Leveraged & Inverse ETFs Way Up
Direxion partnered with Compound Insights and Vanda to explore what’s driving the evolution of active trading — and how active traders are using leveraged and inverse funds across equities, single stocks, commodities, and volatility.
